What is William Blair’s Forecast for NuCana Q1 Earnings?

NuCana plc (NASDAQ:NCNA) – Stock analysts at William Blair issued their Q1 2026 earnings estimates for NuCana in a report issued on Thursday, March 20th. William Blair analyst M. Phipps anticipates that the company will earn ($0.01) per share for the quarter. The consensus estimate for NuCana’s current full-year earnings is ($13.42) per share. William Blair also issued estimates for NuCana’s Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at ($0.01) EPS.

NuCana (NASDAQ:NCNA) last issued its earnings results on Thursday, March 20th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($2.43) by $2.11.

NuCana Stock Up 1.3 %

NASDAQ NCNA opened at $0.80 on Monday. NuCana has a twelve month low of $0.69 and a twelve month high of $10.79. The business has a 50-day moving average price of $0.96 and a 200-day moving average price of $1.49. The firm has a market cap of $2.11 million, a price-to-earnings ratio of -0.08 and a beta of 0.89.

Institutional Investors Weigh In On NuCana

Institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC purchased a new position in shares of NuCana in the fourth quarter worth $25,000. Citadel Advisors LLC purchased a new stake in NuCana in the 4th quarter worth $30,000. Virtu Financial LLC bought a new position in shares of NuCana during the 4th quarter valued at about $48,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of NuCana during the fourth quarter valued at about $54,000. 44.00% of the stock is owned by hedge funds and other institutional investors.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.